Immunovant, Inc. aksje
IMVT
After-hours$31.15+0.23 (+0.74%)
Post-Market:$31.25+0.10 (+0.32%)
Laster graf...
Immunovant, Inc.
Market Cap
$6,395,372,544
Åpning30.82
Høy31.31
Lav30.33
Volum1.85M
P/EN/A
Markedsverdi6.4B
52-ukers høy36.28
52-ukers lav14.32
Gj.sn. volum1.82M
UtbytteN/A
Beta0.70
EPS-2.77
Om Immunovant, Inc. aksje
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Selskapsinformasjon
Børs: NasdaqGS (NMS)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
1000 Park Forty Plaza
27713 Durham, United States
27713 Durham, United States
Telefon: + 917 410 3120
Nettside: https://immunovant.com
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.
Anbefaling:1.67 - Køb
Laveste kursmål
24.00
↓ 23.0%
Gjennomsnittlig kursmål
45.76
↑ 46.9%
Median kursmål
45.00
↑ 44.5%
Høyeste kursmål
66.00
↑ 111.9%